Management of Hypertension in Patients with Pneumonia Covid 19: A Literature Review

Abstract

COVID-19 is an infectious respiratory disease caused by SARS-CoV-2. Originating from Wuhan, China, it spread quickly to the entire world. In just 6 months, it's reported no less than 7.700.000 confirmed cases by June 2020. The cause is severe acute respiratory syndrome coronavirus-2. Many organs are affected by Covid-19, especially the heart and lungs. Cardiovascular damage is frequently detected in patients with this condition. We can find troponin and/or creatine kinase increasing. Cytocine storm in Covid-19 can result towards multiple organ failure (MOF), which is life threatening. Cytocine storm manifested in excessive inflammation, hiperferritinemia, a marked increase in proinflammatory cytokines, hemodinamic instability, and lastly, multi organ failure, which can be fatal. From clinical symptoms, many of the patients developed pneumonia and severe acute respiratory distress syndrome, which is the main death cause of Covid-19. Hypertension and heart problems appear to be the highest comorbidity in patients diagnosed with COVID-19 pneumonia and health risk in the environment.  Multisystem involvement of severe COVID-19 patients necessitates a holistic approach to managing COVID-19-associated hypertension.